Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against breast cancer. Although ADCs such as trastuzumab emtansine and trastuzumab deruxtecan have significantly improved survival for patients with breast cancer expressing HER2, there is still controversy over options...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024176219 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586273511964672 |
|---|---|
| author | Hanghang Ma Jianbin Li |
| author_facet | Hanghang Ma Jianbin Li |
| author_sort | Hanghang Ma |
| collection | DOAJ |
| description | Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against breast cancer. Although ADCs such as trastuzumab emtansine and trastuzumab deruxtecan have significantly improved survival for patients with breast cancer expressing HER2, there is still controversy over options after ADCs. The radiotherapy and ablation should also be used as an effective strategy for oligoprogressions. Herein, we conducted a review of ADCs, and then discussed several strategies to maximize the potential benefit to patients with HER2 expression breast cancer. |
| format | Article |
| id | doaj-art-7ddae0fdb5d249b1b79cd069a1543620 |
| institution | Kabale University |
| issn | 2405-8440 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-7ddae0fdb5d249b1b79cd069a15436202025-01-26T05:04:13ZengElsevierHeliyon2405-84402025-02-01113e41590Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancerHanghang Ma0Jianbin Li1Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing, China; Outpatient Department of the 55th Retired Cadre Rest Center in Haidian District, Beijing, ChinaSenior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing, China; Corresponding author. Fifth medical center of PLA general hospital, China.Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against breast cancer. Although ADCs such as trastuzumab emtansine and trastuzumab deruxtecan have significantly improved survival for patients with breast cancer expressing HER2, there is still controversy over options after ADCs. The radiotherapy and ablation should also be used as an effective strategy for oligoprogressions. Herein, we conducted a review of ADCs, and then discussed several strategies to maximize the potential benefit to patients with HER2 expression breast cancer.http://www.sciencedirect.com/science/article/pii/S2405844024176219Antibody-drug conjugateHER2 expressionBreast neoplasmsRisk-taking |
| spellingShingle | Hanghang Ma Jianbin Li Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer Heliyon Antibody-drug conjugate HER2 expression Breast neoplasms Risk-taking |
| title | Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer |
| title_full | Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer |
| title_fullStr | Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer |
| title_full_unstemmed | Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer |
| title_short | Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer |
| title_sort | impact of her2 targeting antibody drug conjugates in treatment strategies for patients with breast cancer |
| topic | Antibody-drug conjugate HER2 expression Breast neoplasms Risk-taking |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024176219 |
| work_keys_str_mv | AT hanghangma impactofher2targetingantibodydrugconjugatesintreatmentstrategiesforpatientswithbreastcancer AT jianbinli impactofher2targetingantibodydrugconjugatesintreatmentstrategiesforpatientswithbreastcancer |